Health Care • Biotechnology: Pharmaceutical Preparations
$18.95 ▲ +1.07
(+5.98%)
MKT CAP: $1.37B • VOL: 3.63M
52W L $6 52W H $21
ROARABLE / RQD
D • 46/100
PIOTROSKI
1 / 9
OMER // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $0 | $0 |
| YoY Revenue Growth % | — | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$122.8M | -$167.0M |
| Operating Margin % | — | — |
| Net Income (GAAP) | $0 | $0 |
| EBITDA (Normalized) | -$122.7M | -$166.8M |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$116.1M | -$148.8M |
| Capital Expenditures (CapEx) | $65.0K | $165.0K |
| Free Cash Flow (FCF) | -$116.2M | -$149.0M |
| FCF Margin % | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% |
| Cash & Short-Term Equivalents | $9.7M | $3.4M |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | -$121.2M | -$182.6M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OMER.